In Lexington, Massachusetts on February 20, 2026, Partner Therapeutics, Inc. (PTx) shared results of a supplementary examination of the eNRGy trial (NCT02912949) focusing on extending treatment with zenocutuzumab in patients with advanced neuregulin 1 fusion-positive (NRG1+) non-small cell cancer. The study delved into the efficacy of this approach in cases where the disease continued to progress. This analysis sheds light on the potential benefits of zenocutuzumab beyond the standard treatment endpoints. The trial encompassed a significant number of participants, highlighting the potential impact of this innovative treatment approach on patients with this specific type of cancer.